• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根据 OMERACT 筛选器 2.1 选择核心领域集:OMERACT 方法。

Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology.

机构信息

From the Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa; Institute for Work & Health; Institute Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Clinical Epidemiology, Amsterdam UMC, Vrije Universiteit Amsterdam; Amsterdam University Medical Centre, Department of Medical Humanities, Amsterdam Public Health, Amsterdam, the Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; Medicine and Epidemiology, Department of Medicine at the School of Medicine, University of Alabama, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Saint-Quentin en Yvelines; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research; Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia.

L.J. Maxwell, PhD, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; B.J. Shea, PhD, Clinical Investigator, Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; D.E. Beaton, PhD, Senior Scientist, Institute for Work & Health, and Associate Professor, Institute Health Policy, Management and Evaluation, University of Toronto; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; M. Boers, MD, PhD, Professor of Clinical Epidemiology, Amsterdam UMC, Vrije Universiteit Amsterdam; S. Grosskleg, OMERACT Secretariat, University of Ottawa; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre; M.A. D'Agostino, MD, PhD, AP-HP, Professor of Rheumatology, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M. de Wit, PhD, OMERACT Patient Research Partner, and Amsterdam University Medical Centre, Department of Medical Humanities, Amsterdam Public Health; L. Gossec, MD, PhD, Professor of Rheumatology, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; J.A. Singh, MBBS, MPH, Professor of Medicine and Epidemiology, Department of Medicine at the School of Medicine, University of Alabama; L.S. Simon, MD, Co-Managing Director of SDG LLC; V. Strand, Biopharmaceutical Consultant, Portola Valley, California, USA; P. Tugwell, MD, MSc, Professor, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute.

出版信息

J Rheumatol. 2019 Aug;46(8):1014-1020. doi: 10.3899/jrheum.181097. Epub 2019 Feb 15.

DOI:10.3899/jrheum.181097
PMID:30770502
Abstract

OBJECTIVE

To describe the Outcome Measures in Rheumatology (OMERACT) Filter 2.1 methodology for core domain set selection.

METHODS

The "OMERACT Way for Core Domain Set selection" framework consists of 3 stages: first, generating candidate domains through literature reviews and qualitative work, then a process of consensus to obtain agreement from those involved, and finally formal voting on the OMERACT Onion. The OMERACT Onion describes the placement of domains in layers/circles: mandatory in all trials/mandatory in specific circumstances (inner circle); important but optional (middle circle); or research agenda (outer circle). Five OMERACT working groups presented their core domain sets for endorsement by the OMERACT community. Tools including a workbook and whiteboard video were created to assist the process. The methods workshop at OMERACT 2018 introduced participants to this framework.

RESULTS

The 5 OMERACT working groups achieved consensus on their proposed core domain sets. After the Methodology Workshop training exercise at OMERACT 2018, over 90% of participants voted that they were confident that they understood the process of core domain set selection.

CONCLUSION

The methods described in this paper were successfully used by the 5 working groups voting on domains at the OMERACT 2018 meeting, demonstrating the feasibility of the process. In addition, participants at OMERACT 2018 expressed increased confidence and understanding of the core domain set selection process after the training exercise. This methodology will continue to evolve, and we will use innovative technology such as whiteboard videos as a key part of our dissemination and implementation strategy for new methods.

摘要

目的

描述风湿病疗效测量标准化倡议(OMERACT)过滤器 2.1 核心领域集选择方法。

方法

“OMERACT 核心领域集选择方法”框架包括 3 个阶段:首先,通过文献回顾和定性研究生成候选领域;然后通过共识过程获得相关人员的一致意见;最后在 OMERACT 洋葱模型上进行正式投票。OMERACT 洋葱模型描述了领域在各层/各圈的位置:所有试验都必须包含的/特定情况下必须包含的(内圈);重要但可选的(中环);或研究议程(外圈)。五个 OMERACT 工作组提出了他们的核心领域集,供 OMERACT 社区认可。创建了工作簿和白板视频等工具来协助该过程。2018 年 OMERACT 方法研讨会上向与会者介绍了该框架。

结果

五个 OMERACT 工作组就其提议的核心领域集达成共识。在 2018 年 OMERACT 方法研讨会的培训练习之后,超过 90%的参与者投票表示,他们有信心理解核心领域集选择过程。

结论

这 5 个工作组在 2018 年 OMERACT 会议上投票选择领域时成功使用了本文所述的方法,证明了该过程的可行性。此外,2018 年 OMERACT 的参与者在培训练习后表示对核心领域集选择过程的信心和理解有所增强。该方法将继续发展,我们将使用白板视频等创新技术作为新方法传播和实施策略的关键部分。

相似文献

1
Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology.根据 OMERACT 筛选器 2.1 选择核心领域集:OMERACT 方法。
J Rheumatol. 2019 Aug;46(8):1014-1020. doi: 10.3899/jrheum.181097. Epub 2019 Feb 15.
2
Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach.支持 OMERACT 核心领域集用于风湿病学试验中的共享决策干预:来自多步骤共识建立方法的结果。
Semin Arthritis Rheum. 2021 Jun;51(3):593-600. doi: 10.1016/j.semarthrit.2021.03.017. Epub 2021 Apr 6.
3
The OMERACT Core Domain Set for Clinical Trials of Shoulder Disorders.OMERACT 肩部疾病临床试验核心域集。
J Rheumatol. 2019 Aug;46(8):969-975. doi: 10.3899/jrheum.181070. Epub 2019 Feb 1.
4
Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set.纳入患者视角以改善糖皮质激素治疗的获益-风险评估:OMERACT 糖皮质激素核心域集。
Semin Arthritis Rheum. 2021 Oct;51(5):1139-1145. doi: 10.1016/j.semarthrit.2021.06.010. Epub 2021 Jun 25.
5
How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0.如何为临床试验选择核心结局指标集:OMERACT 11批准了筛选标准2.0。
J Rheumatol. 2014 May;41(5):1025-30. doi: 10.3899/jrheum.131314. Epub 2014 Mar 1.
6
Defining domains: developing consensus-based definitions for foundational domains in OMERACT core outcome sets.定义领域:为 OMERACT 核心结局集的基础领域制定基于共识的定义。
Semin Arthritis Rheum. 2024 Jun;66:152423. doi: 10.1016/j.semarthrit.2024.152423. Epub 2024 Feb 29.
7
Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop.建立一个更新的幼年特发性关节炎研究核心领域集:来自 OMERACT 2018 JIA 研讨会的报告。
J Rheumatol. 2019 Aug;46(8):1006-1013. doi: 10.3899/jrheum.181088. Epub 2019 Feb 15.
8
Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop.建立用于衡量类风湿性关节炎病情复发的核心领域集:OMERACT 11类风湿性关节炎病情复发研讨会报告
J Rheumatol. 2014 Apr;41(4):799-809. doi: 10.3899/jrheum.131252. Epub 2014 Mar 1.
9
PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.PsAID12 在 2018 年 OMERACT 会议上被临时认可为评估临床试验中银屑病关节炎特异性健康相关生活质量的核心结局测量指标。
J Rheumatol. 2019 Aug;46(8):990-995. doi: 10.3899/jrheum.181077. Epub 2018 Dec 15.
10
Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting.迈向制定一套核心结局指标以评估风湿病学中共享决策干预措施的发展:来自 OMERACT Delphi 调查和共识会议的结果。
J Rheumatol. 2017 Oct;44(10):1544-1550. doi: 10.3899/jrheum.161241. Epub 2017 Aug 1.

引用本文的文献

1
Prioritisation of head, neck, and respiratory outcomes in mucopolysaccharidosis type II: lessons from a rare disease consensus exercise and comparison of parental and clinical priorities.II型黏多糖贮积症中头、颈和呼吸相关结局的优先级确定:罕见病共识活动的经验教训以及家长与临床优先级的比较
Orphanet J Rare Dis. 2025 Feb 26;20(1):88. doi: 10.1186/s13023-025-03581-y.
2
The GenderCOS project: study protocol for the development of two international Core Outcome Sets for genital gender affirming surgery.性别确认手术核心结局集(GenderCOS)项目:制定两项生殖器性别确认手术国际核心结局集的研究方案。
Int J Transgend Health. 2023 Dec 15;26(1):78-87. doi: 10.1080/26895269.2023.2288881. eCollection 2025.
3
Construct validity of PROMIS pain interference, fatigue, and physical function as patient-reported outcomes in adults with idiopathic inflammatory myopathies: An international study from the OMERACT myositis working group.
特发性炎性肌病患者报告结局测量(PROMIS)疼痛干扰、疲劳和躯体功能的结构效度:OMERACT 肌炎工作组的一项国际研究。
Semin Arthritis Rheum. 2024 Oct;68:152534. doi: 10.1016/j.semarthrit.2024.152534. Epub 2024 Aug 10.
4
OMERACT 2023 Systemic Lupus Erythematosus Special Interest Group: Winnowing and Binning Preliminary Candidate Domains for the Core Outcome Set.OMERACT 2023 系统性红斑狼疮特别兴趣小组:核心结局集初步候选领域的筛选和分类。
Semin Arthritis Rheum. 2024 Apr;65:152380. doi: 10.1016/j.semarthrit.2024.152380. Epub 2024 Jan 14.
5
Protocol for a randomised feasibility trial comparing a combined program of education and exercise versus general advice for ankle osteoarthritis.踝关节骨关节炎教育和运动联合方案与一般建议比较的随机可行性试验方案。
J Foot Ankle Res. 2023 Oct 20;16(1):72. doi: 10.1186/s13047-023-00669-1.
6
Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce.迈向系统性红斑狼疮的新型临床结局评估:国际工作组的初步成果。
Nat Rev Rheumatol. 2023 Sep;19(9):592-602. doi: 10.1038/s41584-023-00993-7. Epub 2023 Jul 11.
7
Developing an Outcome Measures in Rheumatology (OMERACT) Core set of Outcome Measures for FOot and ankle disorders in RheumaTic and musculoskeletal diseases (COMFORT): core domain set study protocol.制定风湿病学结局测量指标(OMERACT)核心足部和踝关节疾病结局测量指标集(COMFORT):核心领域集研究方案。
Trials. 2023 Jan 28;24(1):65. doi: 10.1186/s13063-023-07104-7.
8
Identifying common core outcome domains from core outcome sets of musculoskeletal conditions: protocol for a systematic review.从肌肉骨骼疾病核心结局集中识别常见的核心结局领域:一项系统评价方案
Syst Rev. 2022 Nov 19;11(1):248. doi: 10.1186/s13643-022-02120-1.
9
An international Delphi survey and consensus meeting to define the core outcome set for trigeminal neuralgia clinical trials.一项用于定义三叉神经痛临床试验核心结局集的国际 Delphi 调查和共识会议。
Eur J Pain. 2023 Jan;27(1):86-98. doi: 10.1002/ejp.2041. Epub 2022 Oct 4.
10
Protocol for the development of a core domain set for individuals with ankle osteoarthritis.踝关节骨关节炎患者核心领域集的制定方案。
Trials. 2022 Sep 5;23(1):748. doi: 10.1186/s13063-022-06692-0.